CTOs on the Move

Abeo Management Corporation

www.abeo.com

 
abeo is a nationwide medical billing and software company focused on delivering revenue-enhancing services to private practices, hospitals and surgery centers. We bridge the gap between the constant change in healthcare and your changing needs as a result. We know the healthcare landscape; we know the complexities and regulations. Our professional management services, medical billing software and anesthesia advisory services are tailored to improve the operational and financial performance for the specialty of anesthesiology. We blend our employee expertise in anesthesia with process and technology to take efficiency to the next level. Operational best practices play a key role in our ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.abeo.com
  • 5001 LBJ Freeway Suite 320
    Dallas, TX USA 75244
  • Phone: 972.861.1270

Executives

Name Title Contact Details
Joe Ferro
Chief Technology and Innovation Officer Profile

Similar Companies

Seagate Alliance

Seagate Alliance is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Complete Homecare Inc

Complete Homecare Inc is a Tonawanda, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthpia America

Healthpia America is a Palisades Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Parrish Medical Center

Parrish Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Parrish Medical Center is based in Titusville, FL. You can find more information on Parrish Medical Center at www.parrishmed.com

Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.